JMP Securities Reiterates a Buy Rating on Kadmon HoldingsBy Austin Angelo
According to TipRanks.com, King is a 4-star analyst with an average return of 3.9% and a 47.7% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.
Currently, the analyst consensus on Kadmon Holdings is Strong Buy and the average price target is $10, representing a 66.7% upside.
In a report issued on November 9, Jefferies also reiterated a Buy rating on the stock with a $10 price target.
Based on Kadmon Holdings’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $5.7 million and GAAP net loss of $117 million. In comparison, last year the company earned revenue of $7.72 million and had a GAAP net loss of $28.01 million.
Kadmon Holdings, Inc. is a biopharmaceutical company, which discovers, develops, and commercializes small molecules and biologics. It develops product candidates in a number of indications within autoimmune and fibrotic disease, oncology, and genetic disease. It offers ribavirin tablets and capsules, phentermine and topiramate extended-release capsules, and tetrabenazine tablets. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.